Inventiva S.A. (IVA.PA)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. Andrew Obenshain
|
Chief Executive Officer | 152.24k | -- | 1974 |
|
Dr. Pierre Broqua Ph.D.
|
Co-Founder | 411.8k | -- | 1962 |
|
Mr. Jean Volatier
|
Executive VP Finance & Corporate Social Responsibility | 355.57k | -- | 1965 |
|
Dr. Martine Zimmermann Pharm.D.
|
Executive VP of Regulatory Affairs & Quality Assurance and Head of Regulatory Affairs | 226.09k | -- | 1969 |
|
Mr. Jason A. Campagna M.D., Ph.D.
|
President of Research & Development and Chief Medical Officer | 338.18k | -- | 1966 |
|
Mr. Axel-Sven Malkomes
|
Chief Financial Officer | -- | -- | 1967 |
|
Mr. Christopher Benecchi M.B.A.
|
Chief Operating Officer | -- | -- | 1972 |
|
Ms. Jennifer Nava
|
Chief Information Officer | -- | -- | -- |
|
Ms. Susan Coles
|
Chief Legal Officer | -- | -- | 1966 |
|
Ms. Pamela Herbster
|
Chief People Officer | -- | -- | -- |
Inventiva S.A.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 87
Description
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France.
Corporate Governance
Upcoming Events
September 28, 2026 at 3:30 PM UTC
Inventiva S.A. Earnings Date
Recent Events
Recent Events Information Not Available
